Comparative Pharmacology
Head-to-head clinical analysis: LAX LYTE WITH FLAVOR PACKS versus SUFLAVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAX LYTE WITH FLAVOR PACKS versus SUFLAVE.
LAX-LYTE WITH FLAVOR PACKS vs SUFLAVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Osmotic laxative: polyethylene glycol (PEG) retains water in the intestinal lumen, increasing stool volume and stimulating peristalsis. Electrolytes (sodium, potassium, chloride, bicarbonate) prevent electrolyte depletion.
SUFLAVE is a combination of sulfamethoxazole, a sulfonamide antibiotic, and trimethoprim, a dihydrofolate reductase inhibitor. It inhibits bacterial folic acid synthesis by blocking two consecutive steps: sulfamethoxazole competes with PABA to inhibit dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, leading to bactericidal activity.
Oral: 1 to 2 packets (4 to 8 g of polyethylene glycol 3350) dissolved in 4 to 8 ounces of water once daily, as needed for constipation. Maximum: 2 packets per day.
250 mg intravenously every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 20 hours).
Terminal elimination half-life: 3.5 hours (range 2.5–4.5 h) in healthy adults; prolonged in renal impairment (up to 10 h in anuria)
Primarily renal (30-50% unchanged) and biliary/fecal (50-70% as inactive metabolites).
Renal: 70% unchanged; fecal/biliary: 20%; 10% metabolized to inactive glucuronide
Category C
Category C
Laxative
Laxative